Daniel Rabe, Phd Email & Phone Number

Chicago, Il, Us

Chicago, Illinois, United States

Boston, Massachusetts

1. Ability to identify, troubleshoot, and solve complex problems for immunoassay development: I designed a new surface chemistry for functionalizing plastic microfluidic devices using aryl diazonium for immunoassays, resulting in increased stability and capture (<30 viral particles/mL plasma) that has been patented.2. Isolated the first circulating tumor cell derived spheroid model of glioblastoma and characterized its highly metastatic capabilities using orthotopic and cardiac injections, whole genome sequencing, and RNAseq3. Extensive experience with 3D spheroid tumor models.4. Proficiency in developing and troubleshooting new methods in microfluidics leading to the development of cell-specific extracellular vesicle (EV or exosome) capture systems for Triple-negative breast cancer, melanoma, T-cell, and innate immune cell EV isolation.5. Using my new surface coating method, I helped develop, provided preliminary data for, and co-wrote a grant resulting in $2 million in grant funding for the lab (U18 TR003793).6. Led our work developing a SARS-CoV-2 diagnostic assay: managed three research technicians; ensured proper design, conduct, and reporting of research data; provided data for monthly updates to the NIH; and helped develop our pre-EUA submitted the FDA. 7. Helped develop cryopreservation methods for preserving extracellular vesicles for biobanking and future analysis.8. Expertise working in a collaborative team-oriented environments, managing five projects as lead scientist, as evidenced by cross-functional collaborations with 11 groups, resulting in 3 publications.9. High-level technical, statistical, and computer skills with 6 years of experience working with RNAseq data leading to 4 grant applications, 3 conference presentations, and 3 poster presentations at international conferences.10. Ability to identifying process pain points demonstrated by automation of key processes for microfluidic processing of biofluids and assay development.

Chicago, Illinois

Chicago, Illinois

1. Utilizing RNAseq of the tumor and stroma separately, helped to develop a prognostic gene signature for poor outcome in triple-negative breast cancer patients, as well as identify CCL5 as a key molecule for recruiting macrophages to the tumor, resulting 2 fellowships, 3 presentations, 5 posters, 2 publications, and 1 patent.2. Established a new method for isolation of primary macrophages from tumors, allowing me to determine how CCL5-recruited macrophage drive tumor cell invasion and metastasis through secretion of CCL7, TNFR2, and GRN.3. Utilized in vitro assays, xenograft mouse models, cytokine arrays, and multi-color flow cytometry to evaluate immune cell populations and functions in tumors.4. Determined that tumor EVs are a key regulator of macrophage phenotype, regulated by CCL5 expression in the tumor, to drive metastasis. 5. Found that CCL5 regulates EV mRNA cargo utilizing low-input based sequencing platforms that can be used as potential prognostic biomarkers in triple-negative breast cancer.6. Ability to manage several projects as a cross-functional collaborator, utilizing my skills in mouse models, cell isolations, and targeted therapy to help develop new models of therapy in triple-negative breast cancer leading to a publication.7. Mentored, trained, and managed an undergraduate student over 2 years resulting in successful completion of her honors thesis and acceptance to medical school.8. High-level technical, statistical, and computer skills with 5 years of experience working with RNAseq data to identify worse outcome in triple-negative patients.9. Project and budget management skills gained serving as laboratory manager resulting in 1 IBC protocol and 1 IAUCU protocol.10. Mouse models, primary cell isolations, proteomics, RNAseq, flow cytometry, cytokine arrays, cell-cell communication.

1. Experience managing multiple projects including one utilizing Meso Scale assays to identify dynamic changes in plasma levels of Met, VEGR2, HGF, and VEGF as pharmacodynamic biomarkers for Met/VEGFR2 inhibitors in solid tumors resulting in 1 presentation, 1 poster at an international conference, and 3 publications.2. Through a collaboration with the molecular targets lab at the NCI, characterized novel inhibitors of HIF2a found through a screen of natural products to target HIF2a in clear-cell renal cell carcinoma, resulting in 2 stakeholder updates, 1 poster, and 3 additional publications.3. Ability to work independently and within a team, across functional areas to develop novel inhibitors of Met signaling resulting in 4 publications.

Doctor Of Philosophy (Ph.D.), Cancer Biology

Master Of Science (M.S.), Translational Research

Bachelor Of Science (B.S.), Bachelors Of Art (B.A.), Biological Chemistry, Chemistry